Article Text

PDF
Promise and potential pitfalls of anti-VEGF drugs in retinopathy of prematurity
  1. B A Darlow1,
  2. C Gilbert2,
  3. G E Quinn3,
  4. R Azad4,
  5. A L Ells5,
  6. A Fielder6,
  7. A Zin7
  1. 1
    Department of Paediatrics,University of Otago, Christchurch. Christchurch, New Zealand
  2. 2
    International Centre for Eye Health, London School of Hygiene and Tropical Medicine, London, UK
  3. 3
    The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
  4. 4
    Dr Rajendra Prasad Centre for Ophthalmic Sciences, AIIMS, New Delhi, India
  5. 5
    Calgary Retina Consultants, Calgary, Alberta, Canada
  6. 6
    Department of Optometry & Visual Science, City University, London, UK
  7. 7
    Instituto Fernandes Figuera, FIOCRUZ, Rio de Janeiro, Brazil
  1. Professor B Darlow, Christchurch School of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch 8140, New Zealand; brian.darlow{at}otago.ac.nz

Statistics from Altmetric.com

Only rarely does a new treatment offer a real sea change. An example in the field of neonatology is the use of exogenous surfactant for hyaline membrane disease.1 For the eye, anti-vascular endothelial growth factor (VEGF) drugs may be the therapeutic advance of our time, revolutionising the treatment of vasoproliferative retinopathies including age-related macular degeneration and diabetic retinopathy. In his informative editorial, Sears suggests that anti-VEGF therapy may play a similar role in retinopathy of prematurity.2

Retinopathy of prematurity (ROP) is a vasoproliferative disease, and it is therefore not surprising that there is increasing enthusiasm for anti-VEGF drugs.3 4 …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.